Human antibodies to artemin and methods of use thereof

Human antibodies targeting Artemin effectively block its signaling and reduce thermal hyperalgesia, addressing the lack of effective treatments for conditions associated with Artemin activity.

JP7579462B2Active Publication Date: 2024-11-07REGENERON PHARMACEUTICALS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023562889
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-04-20
Filing Date
2022-04-19
Publication Date
2024-11-07
Estimated Expiration
2042-04-19

AI Technical Summary

Technical Problem

Current treatments for conditions associated with Artemin expression or activity, such as pain and migraines, lack effective antibodies that can specifically bind to Artemin and inhibit its signaling or reduce thermal hyperalgesia.

Method used

Development of human antibodies and antigen-binding fragments that specifically bind to Artemin, blocking its interaction with GFRα3, inhibiting signaling through RET receptor tyrosine kinases, and reducing thermal hyperalgesia, with specific amino acid sequences for high affinity and cross-reactivity.

Benefits of technology

The antibodies effectively inhibit Artemin-induced thermal hyperalgesia and reduce Artemin signaling, providing therapeutic potential for conditions like pain and migraines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579462000019
    Figure 0007579462000019
  • Figure 0007579462000020
    Figure 0007579462000020
  • Figure 0007579462000021
    Figure 0007579462000021
Patent Text Reader

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human Artemin. Methods for using the anti-Artemin antibodies and antigen-binding fragments are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] FIELD OF THEINVENTION The present disclosure relates to human antibodies and antigen-binding fragments of human antibodies that specifically bind to Artemin, and methods of use thereof.

[0002] Sequence Listing An official copy of the Sequence Listing is being submitted contemporaneously herewith electronically via EFS-Web as an ASCII-formatted Sequence Listing having the filename 10907WO01_Sequence_Listing_ST25, a creation date of April 19, 2022, and a size of approximately 69,632 kilobytes. The Sequence Listing contained in this ASCII-formatted document is a part of the present specification and is incorporated herein by reference in its entirety. [Background technology]

[0003] background Artemin (ARTN) is a neurotrophic factor that is a member of the glial cell line-derived neurotrophic factor (GDNF) family of ligands. Each GDNF family ligand binds to a glycosylphosphatidylinositol (GPI)-anchored receptor associated with the cell membrane. This family of receptors is called the GDNF family receptor alpha (GFRα) family and is composed of four different receptors, GFRα1-4. ARTN preferentially binds to the receptor GFRα3 and is the only known ligand for GFRα3. ARTN and other GDNF family ligands signal through the RET ("rearranged during transfection") receptor tyrosine kinase, which was originally discovered as a proto-oncogene. RET is activated by GDNF family members only if the ligand first binds to its GFRα receptor (Airaksinen et al, Nature Reviews Neuroscience (2002), 3:383-394 (Non-Patent Document 1)).

[0004] Both ARTN and GFRα3 are highly expressed during development and are involved in sympathetic nervous system development. In adult mice, ARTN is expressed in the testis, uterus, thyroid, prostate, and epididymis, as well as in the olfactory bulb, and in the intestine and mesentery (Airaksinen et al, Nature Reviews Neuroscience (2002), 3:383-394 (Non-Patent Document 1); Airaksinen et al, Brain, Behavior and Evolution, (2006), 68:181-190 (Non-Patent Document 2)). GFRα3 expression in adults is mainly restricted to sensory neurons of the dorsal root ganglion (DRG) (Orozco et al, European J.Neuroscience, (2001), 13:2177-2182 (Non-Patent Document 3)). Mice lacking ARTN or GFRα3 exhibit abnormalities in the migration and axonal projection patterns of the sympathetic nervous system, resulting in abnormal innervation of target tissues (Honma et al., Neuron, (2002), 35:267-282 (Non-Patent Document 4)).

[0005] Several studies have demonstrated the potential role of ARTN and GFRα3 in pain and heat perception. For example, it has been demonstrated that injection of Artemin protein into the hind paw of rodents causes thermal hyperalgesia, and this nociception is enhanced when Artemin is co-injected with NGF (Malin et al, J.Neuroscience, (2006), 26(33):8588-8599 (Non-Patent Document 5)). Other studies have shown that Artemin mRNA expression is upregulated in mouse inflammation models, and Artemin transgenic mice have elevated expression of TRPV1 and TRPA1, as well as increased behavioral sensitivity to heat and cold (Elitt et al, J.Neuroscience, (2006), 26(33):8578-8587 (Non-Patent Document 6)). In addition, Artemin and GFRα3 expression is increased in a rat model of migraine (Shang et al., J Headache Pain, (2016), 17(1):81 (Non-Patent Document 7)) and in dogs treated with radiation therapy (Nolan et al, Radiat Res, (2020), 193(3):241-248 (Non-Patent Document 8)). Artemin expression is also increased in the tongue mucosa of patients with burning mouth syndrome and in a mouse model of burning mouth syndrome (Shinoda et al., PAIN, (2015), 156(12):2528-2537 (Non-Patent Document 9)). [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Airaksinen et al,Nature Reviews Neuroscience(2002),3:383-394 [Non-Patent Document 2] Airaksinen et al,Brain,Behavior and Evolution,(2006),68:181-190 [Non-Patent Document 3] Orozco et al,European J.Neuroscience,(2001),13:2177-2182 [Non-Patent Document 4] Honma et al., Neuron, (2002), 35:267-282 [Non-Patent Document 5] Malin et al, J. Neuroscience, (2006), 26(33):8588-8599 [Non-Patent Document 6] Elitt et al, J. Neuroscience, (2006), 26(33):8578-8587 [Non-Patent Document 7] Shang et al.,J Headache Pain,(2016),17(1):81 [Non-Patent Document 8] Nolan et al,Radiat Res,(2020),193(3):241-248 [Non-Patent Document 9] Shinoda et al.,PAIN,(2015),156(12):2528-2537 Summary of the Invention

[0007] In a first aspect, an isolated antibody or antigen-binding fragment thereof that specifically binds to Artemin is provided. In some embodiments, the antibody is a monoclonal antibody or antigen-binding fragment thereof that binds to human Artemin. In some embodiments, the antibody or antigen-binding fragment thereof has a K of less than 5 nM as measured by a surface plasmon resonance assay at 25° C. D It binds to human artemin.

[0008] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) blocks at least 65% of human artemin binding to a solid support coated with human GFRα3, as measured by ELISA; (b) inhibiting or reducing Artemin-activated signaling through GFRα3 and RET receptor tyrosine kinases; and / or (c) inhibiting or reducing Artemin-induced thermal hyperalgesia in vivo.

[0009] In some embodiments, the antibody or antigen-binding fragment thereof cross-reacts with artemin from at least one non-human species. In some embodiments, the antibody or antigen-binding fragment thereof cross-reacts with monkey artemin. In some embodiments, the antibody or antigen-binding fragment thereof cross-reacts with mouse artemin.

[0010] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, 44, and 64; (b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, 46, and 66; (c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 28, 48, and 68; (d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 32, 52, and 72; (e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 34, 54, and 74; (f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 36, 56, and 76; Includes.

[0011] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or (b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, or (c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56, or (d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 66, HCDR3 comprising the amino acid sequence of SEQ ID NO: 68, LCDR1 comprising the amino acid sequence of SEQ ID NO: 72, LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 76 Includes.

[0012] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) comprising an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, and 62.

[0013] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) comprising an amino acid sequence having at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 30, 50, and 70.

[0014] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or (b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and an LCVR comprising the amino acid sequence of SEQ ID NO: 30; or (c) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and an LCVR comprising the amino acid sequence of SEQ ID NO: 50; or (d) an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and an LCVR comprising the amino acid sequence of SEQ ID NO: 70; Includes.

[0015] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (a) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 18, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 20; or (b) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 38, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 40; or (c) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 58, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 60; or (d) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 78, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 80. Includes.

[0016] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain comprising the amino acid sequence of SEQ ID NO: 40. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 58 and a light chain comprising the amino acid sequence of SEQ ID NO: 60. In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78 and a light chain comprising the amino acid sequence of SEQ ID NO: 80.

[0017] In some embodiments, the antibodies or antigen-binding fragments thereof are fully human.

[0018] In another aspect, a pharmaceutical composition is provided comprising the antibody or antigen-binding fragment thereof and a pharma- ceutically acceptable carrier.

[0019] In another aspect, a nucleic acid molecule is provided that comprises a nucleotide sequence encoding an antibody or antigen-binding fragment thereof. In some embodiments, the nucleic acid molecule comprises one or more nucleotide sequences set forth in Table 9.

[0020] In yet another aspect, expression vectors and host cells comprising the nucleic acid molecules disclosed herein are provided, as are methods of producing anti-Artemin antibodies using the nucleic acid molecules, expression vectors, and host cells disclosed herein.

[0021] In another aspect, a method of inhibiting Artemin-activated signaling in a cell is provided. In some embodiments, the method comprises contacting the cell with an antibody or antigen-binding fragment or pharmaceutical composition disclosed herein, thereby inhibiting Artemin-activated signaling in the cell. In some embodiments, the cell is in a subject. In some embodiments, the target cell is in vitro or ex vivo.

[0022] In another aspect, methods of treating a disease, disorder, or condition associated with Artemin expression or activity are provided. In some embodiments, the methods comprise administering an antibody or antigen-binding fragment thereof, or pharmaceutical composition disclosed herein to a subject in need of treatment (e.g., a subject having a disease, disorder, or condition associated with Artemin expression or activity). In some embodiments, the antibody or antigen-binding fragment thereof, or pharmaceutical composition is administered to the subject in combination with a second therapeutic agent.

[0023] In another aspect, an anti-artemin antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising an anti-artemin antibody or antigen-binding fragment thereof, is provided for use in a method of treating a disease, disorder, or condition associated with Artemin expression or activity. In some embodiments, the method comprises administering an antibody or antigen-binding fragment thereof or pharmaceutical composition disclosed herein to a subject in need of treatment (e.g., a subject having a disease, disorder, or condition associated with Artemin expression or activity). In some aspects, the antibody or antigen-binding fragment thereof or pharmaceutical composition is therapeutically combined with a second therapeutic agent. In some aspects, the antibody or antigen-binding fragment thereof or pharmaceutical composition is combined with a second therapeutic agent.

[0024] In another aspect, there is provided a use of an anti-artemin antibody or antigen-binding fragment thereof, or a pharmaceutical composition comprising an anti-artemin antibody or antigen-binding fragment thereof, in the manufacture of a medicament for use in a method of treating a disease, disorder, or condition associated with Artemin expression or activity. In some embodiments, the method comprises administering an antibody or antigen-binding fragment thereof or pharmaceutical composition disclosed herein to a subject in need of treatment (e.g., a subject having a disease, disorder, or condition associated with Artemin expression or activity). In some aspects, the antibody or antigen-binding fragment thereof or pharmaceutical composition is therapeutically combined with a second therapeutic agent. In some aspects, the antibody or antigen-binding fragment thereof or pharmaceutical composition is combined with a second therapeutic agent.

[0025] In some embodiments, the disease, disorder, or condition is acute pain, chronic pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, postherpetic neuralgia, generalized neuralgia, visceral pain, osteoarthritic pain, gout, radicular pain, sciatica, back pain, head and neck pain, breakthrough pain, post-operative pain, chemotherapy-induced neuropathic pain, radiotherapy-induced neuropathic pain, radiation-related pain, or cancer pain. In some embodiments, the disease, disorder, or condition is migraine, cluster headache, chronic headache, or tension headache.

[0026] Other embodiments will become apparent from consideration of the detailed description that follows. [The present invention 1001] An isolated monoclonal antibody or antigen-binding fragment thereof that specifically binds to human artemin. [The present invention 1002] The antibody has a K of less than 5 nM as measured by surface plasmon resonance at 25° C. D 1. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention, which binds to human Artemin at [The present invention 1003] The antibody, (i) blocks at least 65% of human artemin binding to a solid support coated with human GFRα3, as measured by ELISA; (ii) inhibiting or reducing Artemin-activated signaling through the GFRα3 and RET receptor tyrosine kinases; and / or (iii) inhibiting or reducing Artemin-induced thermal hyperalgesia in vivo; An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention. [The present invention 1004] (a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, 44, and 64; (b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, 46, and 66; (c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 28, 48, and 68; (d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 32, 52, and 72; (e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 34, 54, and 74; (f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 36, 56, and 76; The isolated monoclonal antibody or antigen-binding fragment thereof of any one of 1001 to 1003 of the present invention. [The present invention 1005] (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or (b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, or (c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56, or (d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 66, HCDR3 comprising the amino acid sequence of SEQ ID NO: 68, LCDR1 comprising the amino acid sequence of SEQ ID NO: 72, LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 76 The isolated monoclonal antibody or antigen-binding fragment thereof of any one of 1001 to 1004 of the present invention. [The present invention 1006] An isolated monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1001 to 1005 of the present invention, comprising a heavy chain variable region (HCVR) having an amino acid sequence having at least 85% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, and 62. [The present invention 1007] An isolated monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1001 to 1006 of the present invention, comprising a light chain variable region (LCVR) comprising an amino acid sequence having at least 85% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 30, 50, and 70. [The present invention 1008] (a) an HCVR comprising the amino acid sequence of SEQ ID NO: 2 and an LCVR comprising the amino acid sequence of SEQ ID NO: 10, or (b) an HCVR comprising the amino acid sequence of SEQ ID NO: 22 and an LCVR comprising the amino acid sequence of SEQ ID NO: 30; or (c) an HCVR comprising the amino acid sequence of SEQ ID NO: 42 and an LCVR comprising the amino acid sequence of SEQ ID NO: 50; or (d) an HCVR comprising the amino acid sequence of SEQ ID NO: 62, and an LCVR comprising the amino acid sequence of SEQ ID NO: 70; The isolated monoclonal antibody or antigen-binding fragment thereof of any one of 1001 to 1007 of the present invention. [The present invention 1009] (a) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 18, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 20; or (b) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 38, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 40; or (c) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 58, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 60; or (d) a heavy chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 78, and a light chain comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 80. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of 1001 to 1008 of the present invention. [The present invention 1010] (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 18 and a light chain comprising the amino acid sequence of SEQ ID NO: 20; or (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain comprising the amino acid sequence of SEQ ID NO: 40; or (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 58 and a light chain comprising the amino acid sequence of SEQ ID NO: 60; or (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 78, and a light chain comprising the amino acid sequence of SEQ ID NO: 80. 1009. An isolated monoclonal antibody or antigen-binding fragment thereof of the present invention comprising: [The present invention 1011] 13. The isolated monoclonal antibody or antigen-binding fragment thereof of any one of 1001 to 1010, which is fully human. [The present invention 1012] An isolated monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1001 to 1011 of the present invention, which cross-reacts with artemin derived from a non-human species. [The present invention 1013] A pharmaceutical composition comprising any one of the monoclonal antibodies or antigen-binding fragments thereof of the present invention 1001 to 1012 and a pharma- ceutically acceptable carrier. [The present invention 1014] A nucleic acid molecule comprising a nucleotide sequence encoding any one of the monoclonal antibodies of the present invention 1001 to 1012 or an antigen-binding fragment thereof. [The present invention 1015] A nucleic acid molecule comprising one or more nucleotide sequences set forth in Table 9. [The present invention 1016] An expression vector comprising the nucleic acid molecule of the present invention 1014 or 1015. [The present invention 1017] A host cell comprising an expression vector of the present invention. [The present invention 1018] A method for producing an anti-human Artemin antibody or antigen-binding fragment thereof, comprising introducing an expression vector of the present invention into a host cell, growing the host cell under conditions that allow production of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment produced. [The present invention 1019] A method for inhibiting Artemin-activated signal transduction in a cell, comprising contacting the cell with any one of the monoclonal antibodies or antigen-binding fragments thereof of the present invention 1001 to 1012, or the pharmaceutical composition of the present invention 1013, thereby inhibiting Artemin-activated signal transduction in the cell. [The present invention 1020] The method of claim 1019, wherein the cell is in a subject. [The present invention 1021] A method for treating a disease, disorder, or condition associated with Artemin expression or activity, comprising administering any one of the monoclonal antibodies or antigen-binding fragments thereof of the present invention 1001 to 1012, or the pharmaceutical composition of the present invention 1013, to a subject in need of treatment. [The present invention 1022] The method of the present invention 1021, wherein the disease, disorder, or condition is acute pain, chronic pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, postherpetic neuralgia, generalized neuralgia, visceral pain, osteoarthritic pain, gout, radicular pain, sciatica, back pain, head and neck pain, breakthrough pain, postoperative pain, chemotherapy-induced neuropathic pain, radiotherapy-induced neuropathic pain, radiation-related pain, or cancer pain. [The present invention 1023] The method of claim 1021, wherein the disease, disorder, or condition is migraine, cluster headache, chronic headache, or tension headache. [The present invention 1024] The method of any of claims 1021 to 1023, wherein said monoclonal antibody or antigen-binding fragment thereof, or said pharmaceutical composition is administered to said subject in combination with a second therapeutic agent. [Brief description of the drawings]

[0027] [Figure 1] Binding of different concentrations of hArtemin-MMH (human Artemin) to the Artemin mAb-captured Octet biosensor surface. [Diagram 2] Binding of different concentrations of MfArtemin-MMH (Cynomolgus Artemin) to the Artemin mAb-captured Octet biosensor surface. [Diagram 3] Binding of different concentrations of mArtemin-MMH (mouse Artemin) to the Artemin mAb-captured Octet biosensor surface. [Figure 4] Inhibition of Artemin-induced plantar heat hyperalgesia in animals administered anti-Artemin antibodies (H4H33331P, H4H33335P, H4H33336P, or H4H33349P) or an isotype control antibody (negative control) at 10 mg / kg. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] Detailed Description definition Before describing the invention, it is to be understood that the invention is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is used for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the invention will be limited only by the appended claims.

[0029] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0030] As used herein, the term "about," when used in reference to a particular referenced numerical value, means that the value may vary from the referenced value by up to 1%. For example, as used herein, the expression "about 100" includes 99 and 101, and all values ​​therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0031] The term "artemin" or "ARTN" as used herein refers to a glial cell line-derived neurotrophic factor (GDNF) family ligand. See Baloh et al., Neuron, (1998), 21(6):1291-1302. As used herein, the term "artemin" may refer to a precursor form or a mature form (i.e., processed form), such as a full-length processed form or a fragment thereof. In some embodiments, the term "artemin" refers to a human artemin protein or a fragment thereof. In some embodiments, the artemin protein comprises the amino acid sequence of human artemin or a fragment thereof (e.g., a proteolytically processed portion) as set forth in NCBI Accession No. NP_476432.2. In some embodiments, the artemin protein comprises the amino acid sequence of human artemin or a fragment thereof (e.g., a proteolytically processed portion) as set forth in Uniprot Accession No. Q5T4W7, or an isoform thereof. In some embodiments, the artemin protein comprises the amino acid sequence of an artemin protein or fragment described in US Pat. No. 6,284,540.

[0032] The term "antibody that binds artemin" or "anti-artemin antibody" includes antibodies and antigen-binding fragments thereof that specifically recognize monomeric artemin, as well as antibodies and antigen-binding fragments thereof that specifically recognize dimeric artemin.

[0033] The term "antibody" as used herein refers to an antigen-binding molecule or molecular complex that comprises a set of complementarity determining regions (CDRs) that specifically bind to or interact with a particular antigen (e.g., ARTN). The term "antibody" as used herein includes immunoglobulin molecules, and multimers thereof (e.g., IgM), that comprise four polypeptide chains, i.e., two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. In a typical antibody, each heavy chain comprises a heavy chain variable region (referred to herein as HCVR or VVR). H The heavy chain constant region is made up of three domains, C H 1. C H 2, and C H Each light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H Area and V L The regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), separated by regions that are relatively conserved, termed framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In some embodiments, the FRs of an antibody (or antigen-binding portion thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on the aligned analysis of two or more CDRs.

[0034] The term "antibody" as used herein also includes antigen-binding fragments of a complete antibody molecule. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, "antigen-binding domain" of an antibody, and equivalents as used herein include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of antibodies can be derived from complete antibody molecules using any suitable standard technique, such as, for example, proteolytic digestion or recombinant genetic engineering techniques, involving the manipulation and expression of DNA encoding the antibody variable regions and optionally the constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and engineered, for example, by placing one or more variable and / or constant domains in a suitable configuration, or by using chemical or molecular biology techniques, such as to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids.

[0035] Non-limiting examples of antigen-binding fragments include (i) Fab fragments, (ii) F(ab')2 fragments, (iii) Fd fragments, (iv) Fv fragments, (v) single chain Fv (scFv) molecules, (vi) dAb fragments, and (vii) minimal recognition units consisting of amino acid residues mimicking a hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and other engineered molecules such as shark variable IgNAR domains are also encompassed by the term "antigen-binding fragment" as used herein.

[0036] Antigen-binding fragments of antibodies typically contain at least one variable domain. A variable domain may be of any size or amino acid composition and will generally contain at least one CDR adjacent to, or in frame with, one or more framework sequences. L V associated with domain H In an antigen-binding fragment having a domain, H Domain and V L The domains can be positioned relative to each other in any suitable configuration. For example, the variable region may be a dimer, such as a V H -V H , V H -V L Or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomeric V H Or V L It may include a domain.

[0037] In certain embodiments, an antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody include: (i) a V H -C H 1, (ii) V H -C H 2. (iii) V H -C H 3. (iv) V H -C H 1-C H 2. (v) V H -C H 1-C H 2-C H 3. (vi) V H -C H 2-C H 3. (vii) V H -C L、 (viii) V L -C H 1, (ix) V L -C H 2. (x)V L -C H 3. (xi) V L -CH 1-C H 2. (xii) V L -C H 1-C H 2-C H 3. (xiii) V L -C H 2-C H 3, and (xiv) V L -C L In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to each other or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies may be linked to each other and / or to one or more monomeric V H Domain or V L The variable and constant domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above in non-covalent association (e.g., by disulfide bonds) of the domains.

[0038] The term "antibody" as used herein also includes multispecific (e.g., bispecific) antibodies. Multispecific antibodies or antigen-binding fragments of antibodies typically contain at least two different variable domains, each capable of specifically binding to a separate antigen or a different epitope on the same antigen. Any multispecific antibody format can be adapted for use in conjunction with the antibodies or antigen-binding fragments of antibodies of the present disclosure using routine techniques available in the art. For example, the present disclosure includes methods that include the use of bispecific antibodies, in which one arm of the immunoglobulin is specific for ARTN or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety. Exemplary bispecific formats that may be used in connection with the present disclosure include, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 Bispecific formats include, but are not limited to, bispecific formats (for a review of the aforementioned formats, see, e.g., Klein et al. 2012, mAbs 4:6,1-11, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, where, for example, unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency, and structure. (See, e.g., Kazane et al., J. Am. Chem. Soc. [Epub:Dec.4,2012]).

[0039] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Nevertheless, the human antibodies of the present disclosure may include amino acid residues (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), e.g., in the CDRs, particularly in CDR3, that are not encoded by human germline immunoglobulin sequences. However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0040] The term "recombinant antibody" as used herein is intended to include all antibodies that are prepared, expressed, created, or isolated by recombinant means. This term includes, but is not limited to, antibodies expressed using a recombinant expression vector transfected into a host cell (e.g., Chinese Hamster Ovary (CHO) cell, NS0 cell, BHK cell, or HEK293 cell) or cellular expression system, antibodies isolated from a recombinant combinatorial human antibody library, and non-human animals (e.g., mice, such as mice that are transgenic for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20:6287-6295). In some embodiments, the recombinant antibody is a recombinant human antibody. In some embodiments, the recombinant human antibody has variable and constant domains derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or in vivo somatic mutagenesis when animals transgenic for human Ig sequences are used) and thus the V and VL of the recombinant antibody are expressed using a recombinant expression vector transfected into a host cell (e.g., Chinese Hamster Ovary (CHO) cell, NS0 cell, BHK cell, or HEK293 cell) or cellular expression system. H and V L The amino acid sequence of the region is H Sequence and V L These are sequences that are derived from and related to sequences, but that may not naturally occur within the human antibody germline repertoire in vivo.

[0041] An "isolated antibody" refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which it is naturally present or produced, is an "isolated antibody." An isolated antibody also includes an antibody in situ within a recombinant cell. An isolated antibody is an antibody that has been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0042] The term "specifically binds" or equivalents means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding is at least about 1×10 -6 M or less, e.g., 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M or 10 -12 M (e.g., a smaller K D indicates tighter binding). Methods for determining whether an antibody specifically binds to an antigen are known in the art and include, for example, equilibrium dialysis, surface plasmon resonance (e.g., BIACORE™), biolayer interferometry assays (e.g., Octet® HTX biosensor), solution affinity ELISA, and the like. In some embodiments, specific binding is measured in a surface plasmon resonance assay, for example, at 25° C. or 37° C. An antibody or antigen-binding fragment that specifically binds to an antigen from one species may or may not have cross-reactivity to other antigens, such as orthologous antigens from another species.

[0043] As used herein, "K D The term " equilibrium dissociation constant" refers to the equilibrium dissociation constant of a particular antibody-antigen interaction.

[0044] The term "surface plasmon resonance" as used herein refers to an optical phenomenon that allows analysis of real-time biomolecular interactions through detection of changes in protein concentration within a biosensor matrix, for example, using the BIACORE™ system (Cytiva, Marlborough, Mass.).

[0045] The term "Bio-Layer Interferometry" or "BLI" as used herein refers to an optical technique for measuring real-time biomolecular interactions by analyzing interference patterns caused by the binding of one biomolecule dispensed onto a sample plate to a second biomolecule immobilized on a biosensor plate, for example using the Octet® system (Sartorius AG, Göttingen, Germany).

[0046] The term "epitope" as used herein refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule known as the paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. The term "epitope" also refers to a site on an antigen to which B cells and / or T cells respond. It also refers to the region of an antigen that is bound by the antigen. Epitopes can be either linear or discontinuous (e.g., conformational). Linear epitopes are epitopes that are generated by adjacent amino acid residues in a polypeptide chain. Conformational epitopes are generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. In certain embodiments, epitopes may include determinants that are chemically active surface groups of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain embodiments may have specific three-dimensional structural features, and / or specific charge properties. Epitopes may also be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and contain residues that directly contribute to the affinity of the interaction. Epitopes typically contain at least 3, and more usually at least 5, or 8-10 amino acids in a unique spatial conformation.

[0047] Methods for determining the epitope of an antigen-binding protein, such as an antibody or an antigen-binding fragment, include alanine scanning mutation analysis, peptide blot analysis (Reineke, Methods Mol Biol 2004, 248: 443-463), peptide truncation analysis, crystallographic studies, and NMR analysis. In addition, methods such as epitope exclusion, epitope extraction, and chemical modification of antigens can be used (Tomer, Prot Sci 2000, 9: 487-496). Another method that can be used to identify the amino acids in a polypeptide with which an antigen-binding protein (e.g., an antibody or an antigen-binding fragment) interacts is hydrogen / deuterium exchange (HDX) detected by mass spectrometry. See, for example, Ehring, Analytical Biochemistry 1999, 267: 252-259; Engen and Smith, Anal Chem 2001, 73: 256A-265A.

[0048] The term "substantial identity" or "substantially identical," when used in reference to a nucleic acid or a fragment thereof, indicates that when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 85%, e.g., at least 90%, 91%, 92%, 93%, 94%, about 95%, 96%, 97%, 98%, or 99% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST, or GAP, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule may, in certain cases, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0049] As applied to polypeptides, the terms "substantial identity" and "substantially identical" mean that two peptide sequences, when optimally aligned, share at least about 85% sequence identity, e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity. In some embodiments, residue positions that are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially alter the functional properties of a protein.

[0050] Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between a wild-type protein and its mutant protein. See, for example, GCG version 6.1. Polypeptide sequences can also be compared using FASTA, a program in GCG version 6.1, with default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and percent sequence identity of the regions of the best overlap between the query sequence and the search sequence (Pearson, 2000, supra). Another preferred algorithm for comparing the sequences of the present disclosure to a database containing a large number of sequences from different organisms is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. (See, e.g., Altschul et al., 1990, J. Mol. Biol. 215:403-410 and 1997 Nucleic Acids Res. 25:3389-3402).

[0051] A "variant" of a polypeptide, such as an immunoglobulin, VH, VL, heavy chain, light chain, or CDR, including an amino acid sequence specifically described herein, refers to a polypeptide that includes an amino acid sequence that is at least about 70% to 99.9% (e.g., at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.5, or 99.9%) identical to a reference polypeptide sequence (e.g., as set forth in the sequence listing below) when the comparison is performed by a BLAST algorithm, where the parameters of the algorithm are selected to generate the maximum match between the respective sequences over the entire length of the respective reference sequences. In some embodiments, a variant of a polypeptide includes a polypeptide having an amino acid sequence of a reference polypeptide sequence (e.g., as set forth in the sequence listing below) that is free of one or more (e.g., 1 to 10, or less than 20, or less than 10) missense mutations (e.g., conservative substitutions), nonsense mutations, deletions, or insertions.

[0052] The term "therapeutically effective amount" refers to an amount that produces a desired effect in the subject to which it is administered. The exact amount will depend on the purpose of the treatment and will be ascertainable by one skilled in the art using known techniques (see, for example, Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0053] Anti-Artemin Antibodies and Antigen-Binding Fragments Thereof In one aspect, the present disclosure relates to antibodies and antigen-binding fragments thereof that bind to artemin. Artemin may exist in a precursor form (e.g., preproprotein) or a proteolytically processed form, for example, as described in U.S. Patent No. 6,284,540, which is incorporated herein by reference. In some embodiments, the antibody or antigen-binding fragment thereof binds to the precursor form of artemin or a fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof binds to the proteolytically processed form of artemin or a fragment thereof.

[0054] In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to human artemin (e.g., human proprotein or proteolytically processed forms). In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to human artemin and cross-reacts with artemin from one or more other non-human species, such as, but not limited to, mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus monkey, marmoset, rhesus monkey, or chimpanzee artemin. In some embodiments, the antibody or antigen-binding fragment thereof specifically binds to human artemin and cross-reacts with at least some (e.g., some, but not all) non-human forms of artemin (e.g., mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgus monkey, marmoset, rhesus monkey, or chimpanzee artemin). In some embodiments, the antibody or antigen-binding fragment thereof does not cross-react with artemin from a non-human species.

[0055] In some embodiments, the anti-Artemin antibody or antigen-binding fragment thereof is (a) a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 24, 44, and 64; (b) a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 26, 46, and 66; (c) a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 28, 48, and 68; (d) a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 32, 52, and 72; (e) a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 34, 54, and 74; (f) a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 36, 56, and 76; Includes.

[0056] In some embodiments, an anti-artemin antibody comprises a heavy chain variable region (HCVR) comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, and 62. In some embodiments, an anti-artemin antibody comprises a HCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 22, 42, and 62.

[0057] In some embodiments, an anti-artemin antibody comprises a light chain variable region (LCVR) comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 30, 50, and 70. In some embodiments, an anti-artemin antibody comprises a LCVR comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 30, 50, and 70.

[0058] In some embodiments, the anti-Artemin antibody or antigen-binding fragment thereof is (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, or (b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, or (c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, or (d) HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, HCDR2 comprising the amino acid sequence of SEQ ID NO: 66, and HCDR3 comprising the amino acid sequence of SEQ ID NO: 68 Includes.

[0059] In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2. In some embodiments, an anti-artemin antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, wherein the HCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 18. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:18.

[0060] In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 22. In some embodiments, an anti-artemin antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 22. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, wherein the HCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 22. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 38. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:38.

[0061] In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 42. In some embodiments, an anti-artemin antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 42. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, wherein the HCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 42. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 58. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:58.

[0062] In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 62. In some embodiments, an anti-artemin antibody comprises an HCVR comprising the amino acid sequence of SEQ ID NO: 62. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 66, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 68, wherein the HCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 62. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 78. In some embodiments, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:78.

[0063] In some embodiments, the anti-Artemin antibody or antigen-binding fragment thereof is (a) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or (b) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36; or (c) an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56; or (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 72, LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 76 Includes.

[0064] In some embodiments, an anti-artemin antibody comprises a LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 10. In some embodiments, an anti-artemin antibody comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, an anti-artemin antibody comprises a LCVR comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, wherein the LCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 10. In some embodiments, the anti-artemin antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 20. In some embodiments, the anti-artemin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:20.

[0065] In some embodiments, an anti-artemin antibody comprises a LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 30. In some embodiments, an anti-artemin antibody comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 30. In some embodiments, an anti-artemin antibody comprises a LCVR comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, wherein the LCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 30. In some embodiments, the anti-artemin antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 40. In some embodiments, the anti-artemin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:40.

[0066] In some embodiments, an anti-artemin antibody comprises a LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 50. In some embodiments, an anti-artemin antibody comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 50. In some embodiments, an anti-artemin antibody comprises a LCVR comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56, wherein the LCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 50. In some embodiments, the anti-artemin antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 60. In some embodiments, the anti-artemin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:60.

[0067] In some embodiments, an anti-artemin antibody comprises a LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 70. In some embodiments, an anti-artemin antibody comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 70. In some embodiments, an anti-artemin antibody comprises a LCVR comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 72, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76, wherein the LCVR has at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 70. In some embodiments, the anti-artemin antibody comprises a light chain comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 80. In some embodiments, the anti-artemin antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:80.

[0068] In some embodiments, an anti-artemin antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2, and an LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 10. In some embodiments, the anti-artemin antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 2, and a LCVR comprising the amino acid sequence of SEQ ID NO: 10. In some aspects, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 18, and a light chain comprising the amino acid sequence of SEQ ID NO: 20.

[0069] In some embodiments, an anti-artemin antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 22, and an LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:30. In some embodiments, the anti-artemin antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 22, and a LCVR comprising the amino acid sequence of SEQ ID NO: 30. In some aspects, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 38, and a light chain comprising the amino acid sequence of SEQ ID NO: 40.

[0070] In some embodiments, an anti-artemin antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 42, and an LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO:50. In some embodiments, the anti-artemin antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 42, and a LCVR comprising the amino acid sequence of SEQ ID NO: 50. In some aspects, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 58, and a light chain comprising the amino acid sequence of SEQ ID NO: 60.

[0071] In some embodiments, an anti-artemin antibody comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 66, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 68, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 72, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In some embodiments, an anti-artemin antibody comprises an HCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 62, and an LCVR comprising an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 70. In some embodiments, the anti-artemin antibody comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 62, and a LCVR comprising the amino acid sequence of SEQ ID NO: 70. In some aspects, the anti-artemin antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 78, and a light chain comprising the amino acid sequence of SEQ ID NO: 80.

[0072] In some embodiments, the antibody or antigen-binding fragment thereof binds to the monomeric form of artemin. In some embodiments, the antibody or antigen-binding fragment thereof binds to the dimeric form of artemin. In some embodiments, the antibody or antigen-binding fragment thereof binds to the mature form of artemin protein (e.g., amino acids 108-220 of SEQ ID NO:81).

[0073] In some embodiments, an anti-artemin antibody or antibody-binding fragment of the present disclosure may be linked to or co-expressed with another functional molecule, e.g., another peptide or protein. For example, an antibody or fragment thereof may be operatively linked (e.g., by chemical coupling, genetic fusion, or non-covalent association, or otherwise) to one or more other molecular entities, such as another antibody or antibody fragment, to produce a bispecific or multispecific antibody having a second binding specificity.

[0074] Sequence variants The antibodies and antigen-binding fragments of the present disclosure may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and / or light chain variable domains compared to the corresponding germline sequences from which the individual antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The antibodies of the present disclosure include antigen-binding fragments derived from any of the exemplary amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue in the germline sequence from which the antibody was derived, or to the corresponding residue in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue (such sequence changes are collectively referred to herein as "germline mutations"). Starting with the heavy and light chain variable region sequences disclosed herein, one of skill in the art can readily produce a large number of antibodies and antigen-binding fragments containing one or more individual germline mutations or combinations thereof. In certain embodiments, the V H and / or V LAll of the framework and / or CDR residues within the domain are mutated back to the residues found in the original germline sequence from which the antibody was originally derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1, or the last 8 amino acids of FR4, or only the mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residues are mutated to the corresponding residue in a different germline sequence (i.e., a germline sequence that differs from the germline sequence from which the antibody was originally derived). Furthermore, an antibody or antigen-binding fragment may contain any combination of two or more germline mutations in the framework and / or CDR regions, e.g., certain individual residues are mutated to the corresponding residue in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residue in a different germline sequence. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties, reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present disclosure.

[0075] The present disclosure also includes antibodies or antigen-binding fragments comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein with one or more conservative substitutions. For example, the present disclosure includes antibodies or antigen-binding fragments comprising HCVR, LCVR, and / or CDR amino acid sequences with, for example, 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, 2 or less, or 1 conservative amino acid substitution to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. A "conservative amino acid substitution" is one in which an amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, a conservative amino acid substitution does not substantially alter the functional properties of a protein. Examples of groups of amino acids having side chains with similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine, (2) aliphatic-hydroxyl side chains: serine and threonine, (3) amide-containing side chains: asparagine and glutamine, (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan, (5) basic side chains: lysine, arginine, and histidine, (6) acidic side chains: aspartic acid and glutamic acid, and (7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change that has a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) Science 256:1443-1445. A "moderately conservative" substitution is any change that has a non-negative value in the PAM250 log-likelihood matrix.

[0076] The present disclosure also includes antibodies or antigen-binding fragments comprising HCVR, LCVR, and / or CDR amino acid sequences that are substantially identical to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. In some embodiments, the antigen-binding molecules comprise HCVR, LCVR, and / or CDR amino acid sequences that have at least 85% sequence identity, e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, to a sequence disclosed in Table 1, Table 2, or Table 9. In some embodiments, the antigen binding molecule comprises an HCVR, LCVR, and / or CDR amino acid sequence having at least 85% sequence identity, e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity, to a sequence disclosed in Table 1, Table 2, or Table 9, and the amino acid sequence differences relative to the sequence disclosed in Table 1, Table 2, or Table 9 are conservative substitutions or moderately conservative substitutions.

[0077] In some embodiments, the antibody or antigen-binding fragment thereof is chimeric, humanized, or fully human. In some embodiments, the antibody or antigen-binding fragment thereof is humanized. In some embodiments, the antibody or antigen-binding fragment thereof is fully human.

[0078] Antibodies containing Fc variants In some embodiments, an anti-artemin antibody or antigen-binding fragment thereof is provided that comprises an Fc domain that includes one or more mutations that enhance or decrease antibody binding to the FcRn receptor, e.g., at acidic pH compared to neutral pH. For example, the disclosure includes antibodies or antigen-binding fragments that include one or more mutations in the CH2 and / or CH3 regions of the Fc domain, which mutations increase the affinity of the Fc domain for FcRn in acidic environments (e.g., in endosomes where the pH ranges from about 5.5 to about 6.0). Such mutations can result in increased serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q), 250 and 428 (e.g., L or F), 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T), or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., H / F or Y), or modifications at positions 250 and / or 428, or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include a 428L (e.g., M428L) and a 434S (e.g., N434S) modification, a 428L, a 259I (e.g., V259I), and a 308F (e.g., V308F) modification, a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification, a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification, a 250Q and a 428L modification (e.g., T250Q and M428L), and a 307 and / or a 308 modification (e.g., 308F and / or 308P).

[0079] For example, the present disclosure includes anti-artemin antibodies comprising an Fc domain that comprises one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the foregoing Fc domain mutations, as well as other mutations in antibody variable domains disclosed herein, are contemplated within the scope of the present disclosure.

[0080] Polynucleotides, Vectors, and Host Cells In another aspect, the disclosure provides nucleic acids comprising one or more polynucleotide sequences encoding the antibodies or antigen-binding fragments disclosed herein, as well as vectors (e.g., expression vectors) encoding such polynucleotide sequences, and host cells into which such vectors have been introduced.

[0081] In some embodiments, the nucleic acid molecule comprises one or more polynucleotide sequences encoding an antibody or antigen-binding fragment disclosed in Table 1 or Table 9. In some embodiments, the nucleic acid molecule comprises one or more polynucleotide sequences set forth in Table 2 or Table 9.

[0082] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising HCDR1, HCDR2, and HCDR3 of SEQ ID NOs: 4, 6, and 8, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising the sequence of SEQ ID NO: 2. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 3, 5, and 7. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 1 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 1. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:17 or has at least 90% sequence identity to SEQ ID NO:17 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0083] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising HCDR1, HCDR2, and HCDR3 of SEQ ID NOs: 24, 26, and 28, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising the sequence of SEQ ID NO: 22. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 23, 25, and 27. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 21 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 21. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:37 or has at least 90% sequence identity to SEQ ID NO:37 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0084] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising HCDR1, HCDR2, and HCDR3 of SEQ ID NOs: 44, 46, and 48, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising the sequence of SEQ ID NO: 42. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 43, 45, and 47. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 41 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 41. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:57 or has at least 90% sequence identity to SEQ ID NO:57 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0085] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising HCDR1, HCDR2, and HCDR3 of SEQ ID NOs: 64, 66, and 68, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an HCVR comprising the sequence of SEQ ID NO: 62. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 63, 65, and 67. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 61 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 61. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:77 or has at least 90% sequence identity to SEQ ID NO:77 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0086] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 12, 14, and 16, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising the sequence of SEQ ID NO: 10. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 11, 13, and 15. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 9 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 9. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:19 or has at least 90% sequence identity to SEQ ID NO:19 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0087] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 32, 34, and 36, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising the sequence of SEQ ID NO: 30. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 31, 33, and 35. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 29 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 29. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:39 or has at least 90% sequence identity to SEQ ID NO:39 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0088] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 52, 54, and 56, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising the sequence of SEQ ID NO: 50. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 51, 53, and 55. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 49 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 49. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:59 or has at least 90% sequence identity to SEQ ID NO:59 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0089] In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising LCDR1, LCDR2, and LCDR3 of SEQ ID NOs: 72, 74, and 76, respectively. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence encoding an LCVR comprising the sequence of SEQ ID NO: 70. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NOs: 71, 73, and 75. In some embodiments, the nucleic acid molecule comprises a polynucleotide sequence of SEQ ID NO: 69 or has at least 90% sequence identity (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity) to SEQ ID NO: 69. In some embodiments, the nucleic acid molecule comprises the polynucleotide sequence of SEQ ID NO:79 or has at least 90% sequence identity to SEQ ID NO:79 (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity).

[0090] In some embodiments, compositions are provided that include one or more nucleic acid molecules disclosed herein (e.g., a first nucleic acid molecule comprising a polynucleotide sequence encoding the HCVR of an anti-artemin antibody, and a second nucleic acid molecule comprising a polynucleotide sequence encoding the LCVR of an anti-artemin antibody).

[0091] The present disclosure also provides recombinant expression vectors carrying one or more nucleic acid molecules disclosed herein, as well as host cells into which such vectors have been introduced. In some embodiments, two or more expression vectors are provided (e.g., a first expression vector comprising a first nucleic acid molecule comprising a polynucleotide sequence encoding the HCVR of an anti-artemin antibody, and a second expression vector comprising a second nucleic acid molecule comprising a polynucleotide sequence encoding the LCVR of an anti-artemin antibody). In some embodiments, the expression vector comprises two or more nucleic acid molecules (e.g., an expression vector comprising (i) a first nucleic acid molecule comprising a polynucleotide sequence encoding the HCVR of an anti-artemin antibody, and (ii) a second nucleic acid molecule comprising a polynucleotide sequence encoding the LCVR of an anti-artemin antibody). Also provided herein are methods of producing anti-artemin antibodies or antigen-binding fragments using the nucleic acid sequences and / or vectors described herein. In some embodiments, the methods of producing antibodies or antigen-binding fragments thereof comprise culturing a host cell comprising one or more nucleic acid sequences and / or expression vectors described herein under conditions that allow for the production of the antibodies or antigen-binding fragments, and recovering the antibodies or antigen-binding fragments so produced.

[0092] In some embodiments, a host cell comprising one or more of the nucleic acid sequences and / or vectors described herein is a prokaryotic cell (e.g., E. coli). In some embodiments, the host cell is a eukaryotic cell, such as a non-human mammalian cell (e.g., a Chinese Hamster Ovary (CHO) cell, an NS0 cell, a BHK cell, or a HEK293 cell). Also provided herein are methods of producing anti-artemin antibodies or antigen-binding fragments thereof by culturing the host cell under conditions that allow for the production of the antibody or antigen-binding fragment, and recovering the antibodies and antigen-binding fragments so produced.

[0093] Characterization of anti-Artemin antibodies The present disclosure includes antibodies and antigen-binding fragments thereof that bind to human Artemin with high affinity. In some embodiments, the present disclosure includes antibodies and antigen-binding fragments thereof that bind to human Artemin with high affinity, e.g., ... D (e.g., at 25° C.) and antigen-binding fragments thereof that bind to human ARTN. In some embodiments, the human ARTN is a mature form of ARTN, e.g., amino acids 108-220 of the human ARTN protein sequence set forth in SEQ ID NO:81. In certain embodiments, the antibodies or antigen-binding fragments of the disclosure have a K of less than about 5 nM, less than about 1 nM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM, less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, less than about 4 pM, less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM, or less than about 0.05 pM as measured by a surface plasmon resonance assay, e.g., using the assay format defined in Example 2 herein or a substantially similar assay. D It binds to human ARTN.

[0094] In some embodiments, the present disclosure includes antibodies and antigen-binding fragments thereof that bind to human ARTN with a dissociation half-life (t1 / 2) of greater than about 30 minutes, as measured by surface plasmon resonance or biolayer interferometry at 25° C., for example, using an assay format defined in Example 2 herein or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments of the present disclosure bind to human ARTN with a t1 / 2 of greater than about 30 minutes, greater than about 40 minutes, greater than about 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than about 80 minutes, greater than about 90 minutes, greater than about 100 minutes, greater than about 150 minutes, greater than about 200 minutes, greater than about 250 minutes, or greater than about 300 minutes, as measured by surface plasmon resonance at 25° C., for example, using an assay format defined in Example 2 herein or a substantially similar assay.

[0095] In some embodiments, the present disclosure includes antibodies and antigen-binding fragments thereof that block ARTN protein binding to GFRα3. In some embodiments, the present disclosure includes antibodies and antigen-binding fragments thereof that block monomeric ARTN (e.g., human, cynomolgus monkey, and / or mouse ARTN) protein binding to human GFRα3, as measured by blocking ELISA assay, for example, using the assay format defined in Example 2 herein or a substantially similar assay. In certain embodiments, the antibodies or antigen-binding fragments of the present disclosure block at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, or at least 90% of human ARTN binding to human GFRα3, as measured by blocking ELISA, for example, using the assay format defined in Example 3 herein or a substantially similar assay.

[0096] In some embodiments, the disclosure includes antibodies and antigen-binding fragments thereof that inhibit Artemin-mediated cell signaling. In some embodiments, the disclosure includes antibodies and antigen-binding fragments thereof that inhibit Artemin-mediated cell signaling, e.g., as measured using a bioassay in a cell line expressing human GFRα3 and human RET as described in Example 4, or a substantially similar assay.

[0097] Epitope mapping and related techniques In some embodiments, the epitope on ARTN that the antibody of the present disclosure binds to may consist of a single contiguous sequence of three or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids of the ARTN protein. Alternatively, the epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) of ARTN. In some embodiments, the antibody of the present disclosure may interact with amino acids contained within an ARTN monomer or with amino acids on two different chains of an ARTN dimer. The term "epitope" as used herein refers to an antigenic determinant that interacts with a specific antigen-binding site in the variable region of an antibody molecule, known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different regions on an antigen and have different biological effects. An epitope may be either conformational or linear. A conformational epitope is generated by spatially juxtaposed amino acids from different segments of a linear polypeptide chain. A linear epitope is an epitope generated by adjacent amino acid residues in a polypeptide chain. In certain circumstances, an epitope may include a sugar, phosphoryl, or sulfonyl moiety on an antigen.

[0098] Various techniques known to those skilled in the art can be used to determine whether an antibody "interacts with one or more amino acids" in a polypeptide or protein. Exemplary techniques that can be used to determine the epitope or binding domain of a particular antibody include routine cross-blocking assays, such as those described in Antibodies, Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY), point mutagenesis (e.g., alanine scanning mutagenesis, arginine scanning mutagenesis, etc.), peptide blot analysis (Reineke, 2004, Methods Mol Biol 248:443-463), protease protection, and peptide cleavage analysis. In addition, methods such as epitope excision, epitope extraction, and chemical modification of antigens can be used (Tomer, 2000, Protein Science 9:487-496). Another method that can be used to identify the amino acids in a polypeptide that an antibody interacts with is hydrogen / deuterium exchange detected by mass spectrometry. Typically, hydrogen / deuterium exchange involves deuterium labeling a protein of interest followed by binding of an antibody to the deuterium-labeled protein. The protein / antibody complex is then transferred to water, allowing hydrogen-deuterium exchange to occur at all residues except those protected by the antibody (which remain deuterium-labeled). After dissociation of the antibody, the target protein is subjected to protease cleavage and mass spectrometry analysis, thereby revealing deuterium-labeled residues that correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) Analytical Biochemistry 267(2):252-259; Engen and Smith (2001) Anal. Chem. 73:256A-265A. X-ray crystallography can also be used to identify amino acids within a polypeptide with which an antibody interacts.

[0099] In some embodiments, the disclosure provides anti-Artemin antibodies that bind to the same epitope as a specific exemplary antibody described herein (e.g., an antibody comprising any of the amino acid sequences set forth in Table 1 or Table 9 below).

[0100] In some embodiments, the disclosure provides anti-artemin antibodies that compete with any of the specific exemplary anti-artemin antibodies described herein for binding to ARTN.

[0101] Those skilled in the art can determine whether a particular antibody binds to the same epitope as the reference antibody of the present disclosure or competes for binding by using routine methods known in the art. For example, to determine whether a test antibody binds to the same epitope on ARTN as the reference antibody of the present disclosure, the reference antibody is first bound to ARTN protein. Then, the ability of the test antibody to bind to ARTN protein is evaluated. If the test antibody can bind to ARTN after saturation binding with the reference antibody, it can be concluded that the test antibody binds to an epitope on ARTN different from the reference antibody. On the other hand, if the test antibody cannot bind to ARTN after saturation binding with the reference antibody, the test antibody may bind to the same epitope on ARTN as the epitope bound by the reference antibody of the present disclosure. Then, additional routine experiments (e.g., peptide mutation and binding analysis) can be carried out to confirm whether the observed lack of binding of the test antibody is actually due to binding to the same epitope as the reference antibody, or whether steric blocking (or another phenomenon) is the cause of the observed lack of binding. This type of experiment can be performed using ELISA, RIA, Biacore, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art. According to certain embodiments of the present disclosure, two antibodies bind to the same (or overlapping) epitope if, for example, 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antibody inhibits the binding of the other antibody by at least 50%, but preferably 75%, 90%, or even 99%, as measured in a competitive binding assay (see, for example, Junghans et al., Cancer Res. 1990:50:1495-1502). Alternatively, two antibodies are considered to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody. Two antibodies are considered to have "overlapping epitopes" if only the subset of amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody.

[0102] To determine whether a test antibody or its antigen-binding fragment competes for binding with a reference antigen-binding molecule, the above-mentioned binding methodology is carried out in two directions: in the first direction, the reference antibody is bound to ARTN protein under saturating conditions, followed by evaluation of the binding of the test antibody to ARTN protein. In the second direction, the test antibody is bound to ARTN protein under saturating conditions, followed by evaluation of the binding of the reference antibody to ARTN protein. In both directions, if only the first (saturating) antibody is able to bind to the ARTN protein, it is concluded that the test antibody and the reference antibody compete for binding to ARTN. As will be understood by those skilled in the art, an antibody that competes for binding with a reference antibody may not necessarily bind to the same epitope as the reference antibody, but may sterically block the binding of the reference antibody by binding to overlapping or adjacent epitopes.

[0103] Preparation of antibodies The antibodies disclosed herein can be prepared by any antibody generation technique known in the art. In certain embodiments, one or more of the individual components of the antibody (e.g., heavy and light chains) are derived from a chimeric antibody, a humanized antibody, or a fully human antibody. Methods for producing such antibodies are well known in the art. For example, one or more of the heavy and / or light chains of the antibody of the present disclosure can be prepared using VELOCIMMUNE™ technology. Using VELOCIMMUNE™ technology (or any other human antibody generation technique), a high affinity chimeric antibody against a particular antigen (e.g., ARTN) with a human variable region and a mouse constant region is first isolated. The antibody is characterized and selected for desirable characteristics including affinity, selectivity, epitope, etc. The mouse constant region is replaced with the desired human constant region to generate a fully human heavy and / or light chain that can be incorporated into the antibody.

[0104] In some embodiments, antibodies can be generated by administering an immunogen (e.g., a peptide shown in SEQ ID NO: 82, optionally conjugated to a carrier) to mice, optionally in combination with an adjuvant. After immunization, splenocytes are harvested and fused with mouse myeloma cells to maintain their viability and form hybridoma cell lines. The hybridoma cell lines are screened and selected to identify cell lines that produce Artemin-specific antibodies. Alternatively, DNA encoding an antigen-specific chimeric antibody, or the variable domains of the light and heavy chains, can be directly isolated from antigen-positive B cells without fusion to myeloma cells, as described in US2007 / 0280945 or WO2016077666, each of which is incorporated by reference in its entirety.

[0105] In some embodiments, genetically engineered animals may be used to generate human antibodies. Non-limiting exemplary transgenic mice and methods for generating antibodies from transgenic mice are described in US8,697,940, US10,130,081, US10,561,124, and US10,640,800, the entire contents of each of which are incorporated herein by reference. As used herein, "fully human" refers to an antigen-binding molecule, such as an antibody, or an antigen-binding fragment or immunoglobulin domain thereof, that comprises an amino acid sequence encoded by DNA derived from a human sequence over the entire length of each polypeptide of the antigen-binding molecule, antibody, antigen-binding fragment, or immunoglobulin domain thereof. In some cases, the fully human sequence is derived from a protein endogenous to humans. In other cases, the fully human protein or protein sequence comprises a chimeric sequence in which each component sequence is derived from a human sequence. Without being bound to any one theory, chimeric proteins or sequences are generally designed to minimize the generation of immunogenic epitopes at the junctions of the component sequences, e.g., compared to any wild-type human immunoglobulin region or domain.

[0106] biological equivalent The present disclosure encompasses proteins having amino acid sequences that differ from the amino acid sequences of the described antibodies, but that retain the ability to bind to ARTN. Such variant molecules contain one or more additions, deletions, or substitutions of amino acids compared to the parent sequence, but exhibit essentially the same biological activity as the described antibody. Similarly, the nucleic acid sequences encoding the antibodies of the present disclosure encompass sequences that contain one or more additions, deletions, or substitutions compared to the disclosed sequences, but that encode antibodies or antibody fragments that are essentially biologically equivalent to the antibodies disclosed herein.

[0107] The present disclosure includes antibodies that are biologically equivalent to any of the exemplary antibodies described herein. Two antibodies are considered to be biologically equivalent if they are pharmaceutical equivalents or pharmaceutical substitutes, e.g., when administered in the same molar dose under similar experimental conditions, either in single or multiple doses, and the rate and extent of absorption do not show significant differences. Some antibodies are considered to be equivalent or pharmaceutical substitutes if their degree of absorption, but not their rate of absorption, is equivalent, and furthermore, such differences in absorption rate are intentional, reflected in labeling, and are not essential for obtaining effective body drug concentrations in chronic use, and are not considered medically significant for the particular pharmaceutical product being studied.

[0108] In one embodiment, two antibodies are bioequivalent if there are no clinically meaningful differences in their safety, purity, and potency.

[0109] In one embodiment, the two antibodies are bioequivalent if a patient can be switched between a first antibody (e.g., a reference product) and a second antibody (e.g., a biological product) one or more times without an expected increased risk of adverse effects, including clinically significant changes in immunogenicity or reduced efficacy, compared to continued therapy without such switching.

[0110] In one embodiment, two antibodies are biologically equivalent if they both act through one or more common mechanisms of action for one or more conditions of use to the extent that such mechanisms are known.

[0111] Bioequivalence may be demonstrated by in vivo and in vitro methods. Non-limiting examples of bioequivalence measurements include, for example, (a) in vivo tests in humans or other mammals where the concentration of an antibody or its metabolites is measured in blood, plasma, serum, or other biological fluid as a function of time, (b) in vitro tests that correlate with and reasonably predict human in vivo bioavailability data, (c) in vivo tests in humans or other mammals where the relevant acute pharmacological effect of the antibody (or its target) is measured as a function of time, and (d) well-controlled clinical trials that demonstrate the safety, efficacy, or bioavailability or bioequivalence of an antibody.

[0112] Biologically equivalent variants of the exemplary antibodies described herein can be constructed, for example, by making various substitutions of residues or sequences, or by deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues that are not essential for biological activity can be deleted or replaced with other amino acids to prevent the formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. In other embodiments, biologically equivalent antibodies can include the exemplary antibodies described herein that contain amino acid changes that modify the glycosylation characteristics of the antibody, for example, mutations that eliminate or remove glycosylation.

[0113] Pharmaceutical Compositions In another aspect, the present disclosure provides pharmaceutical compositions comprising the anti-artemin antibodies and antigen-binding fragments disclosed herein. The pharmaceutical compositions are formulated with one or more pharma- ceutically acceptable vehicles, carriers, and / or excipients. A variety of pharma- ceutically acceptable carriers and excipients are well known in the art. See, for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. In some embodiments, the carrier is suitable for intravenous, intramuscular, oral, intraperitoneal, intrathecal, transdermal, topical, or subcutaneous administration.

[0114] In some embodiments, the pharmaceutical composition includes an injectable preparation, such as a dosage form for intravenous, subcutaneous, intradermal, and intramuscular injection, infusion, and the like. These injectable preparations can be prepared by known methods. For example, the injectable preparations can be prepared, for example, by dissolving, suspending, or emulsifying the above-described antibody or its salt in a sterile aqueous or oily medium conventionally used for injection. The aqueous medium for injection includes, for example, physiological saline, an isotonic solution containing glucose, and other auxiliary agents, which can be used in combination with a suitable solubilizing agent such as alcohol (e.g., ethanol), polyalcohol (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)]. The oily medium includes, for example, sesame oil, soybean oil, and the like, which can be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, and the like. The injection solution thus prepared can be filled into a suitable ampoule.

[0115] The dose of the antibody administered to a patient according to the method of the present disclosure may vary depending on the age and size of the patient, symptoms, condition, route of administration, and the like. The dose is typically calculated according to body weight or body surface area. The frequency and duration of treatment can be adjusted depending on the severity of the condition. The effective dose and schedule for administering the pharmaceutical composition disclosed herein can be empirically determined, for example, by monitoring the progress of the patient by periodic evaluation, and the dose can be adjusted accordingly. Furthermore, inter-species scaling of the dose can be performed using methods well known in the art (e.g., Mordenti et al., 1991, Pharmaceut. Res. 8:1351).

[0116] A variety of delivery systems are known and can be used to administer the pharmaceutical compositions, such as, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al., 1987, J. Biol. Chem. 262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. In some embodiments, the pharmaceutical compositions disclosed herein are administered intravenously. In some embodiments, the pharmaceutical compositions disclosed herein are administered subcutaneously.

[0117] In some embodiments, the antibody or pharmaceutical composition comprising the antibody disclosed herein is contained within a container. Thus, in another aspect, a container is provided that comprises the antibody or pharmaceutical composition disclosed herein. For example, in some embodiments, the antibody or pharmaceutical composition is contained within a container selected from the group consisting of a glass vial, a syringe, a pen delivery device, and an autoinjector.

[0118] In some embodiments, the antibody or pharmaceutical composition of the disclosure is delivered using a standard needle and syringe, e.g., subcutaneously or intravenously. In some embodiments, the syringe is a pre-filled syringe. In some embodiments, a pen delivery device or an autoinjector is used to deliver the antibody or pharmaceutical composition of the disclosure (e.g., for subcutaneous delivery). The pen delivery device can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable cartridge that contains the pharmaceutical composition. Once all of the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In disposable pen delivery devices, there is no replaceable cartridge. Rather, disposable pen delivery devices are sold in a pre-filled state, where the pharmaceutical composition is held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

[0119] Examples of suitable pen and autoinjector type delivery devices include the AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), the DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), the HUMALOG MIX 75 / 25™ pen, the HUMALOG™ pen, the HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), the NOVOPEN™ I, II, and III (Novo Nordisk, Copenhagen, Denmark), the NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), the BD™ pen (Becton Dickinson, Franklin Lakes, NJ), the OPTIPEN™, the OPTIPEN PRO™, the OPTIPEN Examples of disposable pen-type delivery devices that have applications in the subcutaneous delivery of the pharmaceutical compositions of the present invention include, but are not limited to, SOLOSTAR pen (sanofi-aventis), FLEXPEN (Novo Nordisk), and KWIKPEN (Eli Lilly), SURECLICK autoinjector (Amgen, Thousand Oaks, CA), PENLET (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA pen (Abbott Labs, Abbott Park IL).

[0120] In some embodiments, the antibody or pharmaceutical composition is delivered using a controlled release system. In one embodiment, a pump can be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201). In another embodiment, a polymeric material can be used. See Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, the controlled release system can be placed in the vicinity of the target of the composition, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer, 1990, Science 249:1527-1533.

[0121] In some embodiments, the pharmaceutical compositions for use described herein are prepared in dosage forms with unit doses suitable for adapting the dose of the active ingredient. Such dosage forms in unit doses include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. In some embodiments, the amount of the antigen-binding molecule contained in the dosage form is about 5 to about 500 mg, for example, about 5 to about 100 mg or about 10 to about 250 mg.

[0122] Therapeutic Use In another aspect, the disclosure provides methods of using the anti-artemin antibodies and antigen-binding fragments disclosed herein. In some embodiments, the anti-artemin antibodies and antigen-binding fragments disclosed herein are useful for treating, preventing, and / or ameliorating any disease, disorder, or condition associated with Artemin expression (e.g., overexpression) or activity. In some embodiments, the disease, disorder, or condition is pain, such as acute pain, chronic pain, neuropathic pain, inflammatory pain, neuralgia (e.g., trigeminal neuralgia, postherpetic neuralgia, or generalized neuralgia), visceral pain, osteoarthritic pain, gout, radicular pain, sciatica, back pain, head and neck pain, breakthrough pain, postoperative pain, chemotherapy-induced neuropathic pain, radiation therapy-induced neuropathic pain, radiation-related pain, or cancer pain (e.g., pain associated with osteosarcoma or pancreatic cancer).

[0123] In some embodiments, the anti-artemin antibodies and antigen-binding fragments disclosed herein are useful for treating, preventing, and / or ameliorating headaches or headache-related pain (e.g., migraine headaches, cluster headaches, chronic headaches, or tension headaches).

[0124] In some embodiments, the antibodies or antigen-binding fragments thereof disclosed herein are also used to treat any of the following conditions: non-malignant acute pain, chronic pain, or bone fracture pain, pain associated with arthritis (e.g., osteoarthritis or rheumatoid arthritis), spinal stenosis, neuropathic low back pain, myofascial pain syndrome, fibromyalgia, temporomandibular joint pain, visceral pain, chronic headache pain, tension headaches including cluster headaches, migraine headaches, diabetic neuropathy, HIV-associated neuropathy, Charcot-Marie-Tooth neuropathy, hereditary sensory neuropathy, peripheral nerve injury, painful neuromas, ectopic proximal and distal drainage, radiculopathy, chemotherapy-induced In some embodiments, the compound may be used to treat chronic neuropathic pain, radiation therapy induced neuropathic pain, post mastectomy pain, central pain, spinal cord injury pain, post stroke pain, thalamic pain, complex regional pain syndrome (CRPS), phantom limb pain, intractable pain, musculoskeletal pain, joint pain, acute gout pain, pruritus, mechanical low back pain, neck pain, tendonitis, injury / exercise pain, abdominal pain, chest pain including cardiac pain, pelvic pain, renal colic, acute obstetric pain including labour pain, imperial incision pain, burn and trauma pain, endometriosis, shingles pain, breakthrough pain, orofacial pain including sinus or tooth pain, multiple sclerosis pain, leprosy pain, Guillain-Barre pain, and burning mouth syndrome.

[0125] Dosage and Administration Regimen In some embodiments, the amount of anti-artemin antibody or antigen-binding fragment administered to a subject according to the methods disclosed herein is a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" is the amount in which it is administered that produces a desired effect.

[0126] In some embodiments, the antibody is administered to the subject as a weight-based dose. A "weight-based dose" (e.g., a dose in mg / kg) is a dose of the antibody that will vary depending on the weight of the subject.

[0127] In other embodiments, the antibody is administered as a fixed dose. A "fixed dose" (e.g., a dose in mg) means that one dose of antibody is used for all subjects, regardless of any specific subject-related factors, such as body weight. In one particular embodiment, the fixed dose of antibody is based on a given body weight or age.

[0128] Typically, a suitable dose of antibody can be in the range of about 0.001 to about 200.0 milligrams per kilogram of recipient body weight, generally in the range of about 1 to 50 mg per kilogram of recipient body weight. For example, the antibody can be administered at about 0.1 mg / kg, about 0.2 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 1.5 mg / kg, about 2 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 40 mg / kg, or about 50 mg / kg per single dose. Values ​​and ranges intermediate to the recited values ​​are also intended to be part of this disclosure.

[0129] In some embodiments, the antibody is administered as a fixed dose of about 5 mg to about 2500 mg. In some embodiments, the antibody is administered as a fixed dose of about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg , about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1500 mg, about 2000 mg, or about 2500 mg. Values ​​and ranges intermediate to the recited values ​​are also intended to be part of this disclosure.

[0130] In some embodiments, the antibody is administered to a subject at a dosing frequency of about 4 times per week, twice per week, once per week, once every 2 weeks, once every 3 weeks, once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 8 weeks, once every 12 weeks, or less frequently, so long as a therapeutic response is achieved.

[0131] In some embodiments, multiple doses of the antibody disclosed herein are administered to a subject over a defined time course. In some embodiments, the method of the disclosure includes sequentially administering multiple doses of the antibody to a subject. As used herein, "sequentially administering" means that each dose of the antibody is administered to the subject at different times, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). In some embodiments, the method of the disclosure includes sequentially administering a single initial dose of the antibody to a patient, followed by one or more secondary doses of the antibody, optionally followed by one or more tertiary doses of the antibody.

[0132] The terms "initial dose", "secondary dose", and "tertiary dose" refer to the temporal order of administration of the antibody. Thus, the "initial dose" is the dose administered at the beginning of the treatment regimen (also referred to as the "loading dose"), the "secondary dose" is the dose administered after the initial administration, and the "tertiary dose" is the dose administered after the secondary administration. In some embodiments, the initial dose, secondary dose, and tertiary dose may all contain the same amount of antibody, but may differ from each other in terms of frequency of administration. In some embodiments, the amount of antibody contained in the initial dose, secondary dose, and / or tertiary dose varies from each other during the course of treatment (e.g., adjusted upwards or downwards as appropriate). In certain embodiments, one or more doses (e.g., 1, 2, 3, 4, or 5) are administered as a "loading dose" at the beginning of the treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered on a less frequent basis. In some embodiments, the initial dose and one or more secondary doses each contain the same amount of antibody. In other embodiments, the initial dose comprises a first amount of antibody and the one or more secondary doses each comprise a second amount of antibody, e.g., the first amount of antibody can be 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, or 5-fold or more than the second amount of antibody.

[0133] In some embodiments, each secondary and / or tertiary dose is administered 1 to 14 weeks (e.g., 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5 or more weeks) after the immediately preceding dose. The phrase "immediately preceding dose" as used herein refers to the dose of antibody that is administered to a patient prior to administration of the exact next dose in a multiple administration sequence, with no intervening doses in the sequence.

[0134] The methods of the disclosure may include administering any number of secondary and / or tertiary doses of an antibody to a patient. For example, in certain embodiments, only a single secondary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) secondary doses are administered to a patient. Similarly, in certain embodiments, only a single tertiary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) tertiary doses are administered to a patient.

[0135] In some embodiments that include multiple secondary doses, each secondary dose is administered with the same frequency as other secondary doses. For example, each secondary dose can be administered to the patient 1, 2, 3, or 4 weeks after the previous dose. Similarly, in some embodiments that involve multiple tertiary doses, each tertiary dose is administered with the same frequency as other tertiary doses. Alternatively, the frequency with which the secondary and / or tertiary doses are administered to the patient can vary over the course of the treatment regimen. The frequency of administration can also be adjusted by the physician during the course of treatment according to the needs of individual patients after clinical examination.

[0136] Combination therapy In some embodiments, the antibodies or antigen-binding fragments of the present disclosure can be used in combination with one or more other therapeutic agents. In some embodiments, the additional therapeutic agent is an antibody, a small molecule, an inhibitory nucleic acid (e.g., RNAi), an antibody drug conjugate, a bispecific antibody, or a combination thereof.

[0137] In some embodiments, the anti-artemin antibodies of the present disclosure may be administered in combination with another artemin inhibitor, an inhibitor of GFRα3 (e.g., an antibody disclosed in WO2014 / 031712, which is incorporated by reference herein), an inhibitor of another GDNF family ligand or receptor, such as an inhibitor of GDNF, neurturin (NRTN), persephin (PSPN), GFRα1, GFRα2, or GFRα4, or a RET inhibitor.

[0138] In some embodiments, the anti-artemin antibody is administered in combination with an additional therapeutic agent that reduces, relieves, or ameliorates pain. Exemplary additional therapeutic agents include COX-2 inhibitors, local anesthetics, NMDA modulators, cannabinoid receptor agonists, P2X family modulators, VR1 antagonists, substance P antagonists, inhibitors of voltage-gated sodium channels (Nav), such as Nav1.7 antagonists, Nav1.8 antagonists, or Nav1.9 antagonists (e.g., antibodies, small molecule inhibitors, or inhibitors against Nav1.7, Nav1.8, or Nav1.9). a cytotoxic nucleic acid), a calcium channel inhibitor, a potassium channel inhibitor, a cytokine inhibitor or cytokine receptor antagonist (e.g., an interleukin-1 (IL-1) inhibitor (rilonacept ("IL-1 trap", Regeneron) or an interleukin-1 receptor (IL-1R) inhibitor, an IL-18 inhibitor, an IL-6 or IL-6R inhibitor, an IL-17 inhibitor, a tumor necrosis factor (TNF) or a TNF receptor inhibitor (e.g., adalimumab), or an inhibitor of TWEAK (T NF-associated WEAK apoptosis inducers, etc.), growth factor inhibitors (e.g., nerve growth factor (NGF) inhibitors such as small molecule NGF antagonists or anti-NGF antibodies), neurotrophic factor inhibitors (e.g., inhibitors of BDNF, TrkA, TrkB, or p75, or another inhibitor of a GDNF family ligand or receptor), anti-epileptic / anti-convulsant drugs (e.g., gabapentin, pregabalin), opioids, morphine, low dose colchicine, aspirin or another NSAID, steroids (e.g., These include, but are not limited to, cyclosporine A, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, inhibitors of acid-sensing ion channels (e.g., ASIC1 or ASIC3), uric acid synthesis inhibitors (e.g., allopurinol), uric acid excretion promoters (e.g., probenecid, sulfinpyrazone, benzbromarone, etc.), and / or corticosteroids.

[0139] The additional therapeutically active ingredient may be administered immediately prior to, simultaneously with, or immediately following administration of an antibody of the present disclosure, and for purposes of this disclosure, such an administration regimen will be considered administration of the antibody "in combination with" the additional therapeutically active ingredient.

[0140] The present disclosure includes pharmaceutical compositions in which an antibody of the disclosure is co-formulated with one or more of the additional therapeutically active ingredients described elsewhere herein. EXAMPLES

[0141] The following examples are presented to provide those skilled in the art with a complete disclosure and description of how to make and use the disclosed methods and compositions, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure.

[0142] Example 1: Generation of human antibodies against human Artemin Antibodies against human Artemin were obtained by immunizing VELOCIMMUNE® mice (i.e., engineered mice containing DNA encoding human immunoglobulin heavy and kappa chain variable regions) with human Artemin antigen (hARTN(A108-G220) with a C-terminal mmH tag, SEQ ID NO:82), followed by a booster immunization with the same immunogen.

[0143] After immunization, antibodies were directly isolated from antigen-positive mouse B cells, for example, as described in U.S. Patent No. 7,582,298, which is incorporated herein by reference. Using this method, fully human anti-hARTN antibodies (i.e., antibodies with human variable domains and human constant domains) were obtained. The anti-ARTN antibodies generated using this method were designated H4H33331P, H4H33335P, H4H33336P, and H4H33349P. The specific biological properties of the exemplary anti-ARTN antibodies generated according to the method of this example are described in the examples below.

[0144] Table 1: Amino acid sequence identifiers TIFF0007579462000001.tif33156

[0145] Table 2: Nucleic acid sequence identifiers TIFF0007579462000002.tif33156

[0146] Example 2: Binding Characterization of Artemin Antibodies Octet conjugation of Artemin monoclonal antibody Binding of artemin to each of the artemin monoclonal antibodies (mAbs) H4H33331P, H4H33335P, H4H33336P, and H4H33349P was determined using a real-time label-free biolayer interferometry (BLI) assay on an Octet HTX biosensor platform (Pall ForteBio Corp.). Tagged Artemin proteins were generated containing the mature region of the human (hArtemin, Uniprot Q5T4W7-1, amino acids A108-G220), cynomolgus monkey (Macaca fascicularis, MfArtemin, XP_015292608.1, amino acids A108-G220; X110G, X111P, X112G, X113S, X114R, X115P, X116R; X indicates the human sequence at those specific positions), or mouse (mArtemin, Uniprot Q9Z0L2-1, amino acids A112-G224) protein fused at the c-terminus to the epitope tag myc-myc-6xHis. The sequence of tagged human artemin designated "hArtemin-MMH" is set forth in SEQ ID NO: 82, the sequence of tagged monkey artemin designated "MfArtemin-MMH" is set forth in SEQ ID NO: 83, and the sequence of tagged mouse artemin designated "mArtemin-MMH" or "msArtemin-MMH" is set forth in SEQ ID NO: 84.

[0147] The entire experiment was carried out in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.02% NaN3 and 0.05% v / v surfactant Tween-20, and 1 mg / mL BSA, pH 7.4 (HBS-EBT) buffer at 25°C with the plate shaking at a speed of 1000 rpm. Different artemin mAbs were first captured on anti-human antibody (AHC)-coated Octet biosensor chips (Fortebio Inc, #18-5064) by immersing the biosensor chips in wells containing 2 μg / mL artemin mAb for 40 s. The artemin mAb-captured biosensor chips were later immersed in wells containing different concentrations (30-3.75 nM, 2-fold serial dilutions) of tagged human, monkey, or mouse artemin protein for 3 min, and their dissociation in HBS-EBT buffer was monitored for 20 min. All Artemin and Artemin mAb samples were prepared in HBS-EBT buffer. Real-time binding responses were monitored throughout the course of the experiment and recorded at the end of all steps.

[0148] The binding of various artemin reagents to different artemin mAbs is reported in Table 3, and concentration-dependent binding data are also provided in Figures 1-3.

[0149] As shown in Table 3 and Figure 1, all four Artemin mAbs bound to hArtemin-MMH at 25°C.

[0150] As shown in Table 3 and Figure 2, all four Artemin mAbs bound to MfArtemin-MMH at 25°C.

[0151] As shown in Table 3 and Figure 3, all four Artemin mAbs bound to mArtemin-MMH at 25°C.

[0152] Table 3. Conjugation of various Artemin reagents to different Artemin mAbs TIFF0007579462000003.tif128148 $indicates that binding of Artemin to the isotype mAb captured surface was not tested at the indicated concentrations.

[0153] Biacore binding kinetics of Artemin monoclonal antibodies Using a real-time surface plasmon resonance Biacore T200 sensor, the equilibrium dissociation constants (K D ) was determined. All binding studies were performed at 25 °C in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% v / v surfactant Tween-20, pH 7.4 (HBS-ET) running buffer. A Biacore CM4 sensor chip surface was first derivatized by amine coupling with anti-myc mAb to capture hArtemin-MMH, MfArtemin-MMH, or mArtemin-MMH. Different concentrations of Artemin mAb (60–2.2 nM, 3-fold serial dilutions) prepared in HBS-EP running buffer were injected over the Artemin capture surface at a flow rate of 50 μL / min for 3 min, and their dissociation in HBS-ET running buffer was monitored for 5 min. At the end of each cycle, the Artemin capture surface was regenerated using a 6 s injection of 20 mM phosphoric acid.

[0154] Association rates (k) were determined by fitting the real-time binding sensorgrams to a 1:1 binding model with mass transport limitations using Scrubber 2.0c curve fitting software. a ) and dissociation rate (k d The binding / dissociation equilibrium constant (K D ) and dissociation half-life (t1 / 2) were calculated from the kinetic rates as follows: K D (M)=k d / k a , and t 1 / 2 (min)=[ln2 / (60*k d )].

[0155] The binding kinetic parameters of artemin binding to different artemin mAbs of the invention at 25° C. are shown in Tables 4-6.

[0156] As shown in Table 4, all four Artemin mAbs had K values ​​ranging from 119 pM to 2.91 nM at 25°C. D values ​​bound to hArtemin-MMH.

[0157] As shown in Table 5, three of the four Artemin mAbs (H4H33331P, H4H33335P, and H4H33349P) had K values ​​ranging from 111 pM to 1.51 nM at 25°C. D Specific binding was also observed for mAb H4H33335P, although binding kinetic parameters could not be determined under the current experimental conditions.

[0158] As shown in Table 6, two of the four Artemin mAbs (H4H33331P and H4H33349P) had K of 113 pM and 346 pM, respectively, at 25°C. D Specific binding was also observed for mAbs H4H33335P and H4H33336P, although binding kinetic parameters could not be determined under the current experimental conditions.

[0159] Table 4. Binding kinetic parameters of different Artemin monoclonal antibodies to hArtemin-MMH at 25°C. TIFF0007579462000004.tif59147 * indicates that no binding was observed under the current experimental conditions (NB).

[0160] Table 5. Binding kinetic parameters of different Artemin monoclonal antibodies to MfArtemin-MMH at 25°C. TIFF0007579462000005.tif59150 * indicates that no binding was observed under the current experimental conditions (NB). # indicates that specific binding was observed, but binding kinetic parameters could not be determined under the current experimental conditions and are therefore not available (NA).

[0161] Table 6. Binding kinetic parameters of different Artemin monoclonal antibodies to mArtemin-MMH at 25°C. TIFF0007579462000006.tif59150 * indicates that no binding was observed under the current experimental conditions (NB). # indicates that specific binding was observed, but binding kinetic parameters could not be determined under the current experimental conditions and are therefore not available (NA).

[0162] Example 3: Anti-ARTN antibody blockade of ARTN binding to GFRα3 To determine the ability of anti-Artemin (ARTN) antibodies to block monomeric human, monkey (Macaca fascicularis), and mouse ARTN protein binding to human GFRα3 (glial cell line-derived neurotrophic factor (GDNF) family receptor alpha 3), multiple Artemin blocking assays were developed using an ELISA-based format.

[0163] The Artemin proteins used in the experiments were hArtemin-MMH, MfArtemin-MMH, or mArtemin-MMH as disclosed above in Example 2. The human GFRα3 used in the experiments is composed of amino acids D32-W382 of UniProtKB Accession No. O60609, with the Fc portion of human IgG1 at the c-terminus, and is referred to as "hGFRa3.hFc" (SEQ ID NO: 85).

[0164] The experiment was carried out using the following procedure: Plates were coated with 2 μg / ml hGFRa3.hFc in PBS on 96-well microtiter plates overnight at 4° C. for all three assays. After overnight coating, non-specific binding sites were then blocked for 1 hour at room temperature using 0.5% (w / v) BSA in PBS. In other microtiter plates, a constant amount of either 75 pM hARTN.mmh, 400 pM mfARTN.mmh, or 150 pM msARTN.mmh was separately combined with anti-ARTN antibodies and an irrelevant IgG4 antibody control in a serial dilution series from 0.0017 nM to 100 nM in PBS + 0.5% BSA. After 1 hour of incubation, the mixture solution was transferred to the microtiter plate coated with hGFRa3.hFc. After 1 hour incubation at room temperature, wells were washed with PBST and plate-bound ARTN was detected using an anti-penta-His antibody conjugated with horseradish peroxidase (HRP) (Qiagen). Plates were then developed using TMB substrate solution (BD Biosciences, #555214) according to the manufacturer's recommendations and absorbance at 450 nm was measured on a Victor X5 plate reader.

[0165] Binding data was analyzed using a sigmoidal dose-response model within Prism™ software (GraphPad). Calculated IC50 values, defined as the concentration of antibody required to block 50% of ARTN.mmh binding to plate-coated hGFRa3.hFc, were used as an indicator of blocking potency. The lower limit of assay (LLOA) of IC50 for hARTN.mmh, mfARTN.mmh, and mARTN.mmh was 18.8 pM, 100 pM, and 37.5 pM, respectively, based on the binding stoichiometry of two artemins to one antibody. If the calculated IC50 value was below the LLOA, less than the LLOA was reported. Percent blocking at 100 nM antibody was calculated based on the background-corrected binding signal observed at the highest antibody concentration tested and reported for all tested antibodies using the formula listed below: TIFF0007579462000007.tif14150

[0166] result A multiple blocking ELISA format was used to assess the ability of anti-ARTN antibodies to block human, monkey, and mouse artemin binding to human GFRa3. In these assays, 75 pM hARTN.mmh, 400 pM mfARTN.mmh, or 150 pM msARTN.mmh were titrated with a wide range of concentrations of anti-ARTN antibodies to assess binding of the three artemin species to hGFRa3.hFc in the presence of the antibodies. Plate-bound ARTN.mmh was detected with an HRP-conjugated anti-penta-His antibody.

[0167] The four tested antibodies potently blocked human, monkey, and mouse Artemin binding to plate-bound human GFRa3 with IC50s below 1 nM and greater than 50% blocking at the highest antibody concentration tested. Blocking IC50s and percent blocking of anti-ARTN antibodies at the highest tested concentration are summarized in Table 7. An irrelevant isotype control antibody showed no blocking activity.

[0168] Table 7. Potency of antibodies blocking binding of human, monkey, and mouse Artemin to human GFRα3 TIFF0007579462000008.tif51150 * Below the lower limit of the assay

[0169] Example 4: Inhibition of Artemin-Mediated Cell Signaling by Artemin Monoclonal Antibodies To evaluate anti-artemin antibody inhibition of artemin-mediated cell signaling, a bioassay was established in HEK293 cells (human embryonic kidney, ATCC, #CRL-1573). HEK293 cells were transduced with a serum response element luciferase reporter (SRE-Luc, SA Biosciences) and engineered to stably express full-length human GFRα3 (amino acids M1-W400 of Genbank accession number NP_001487.2) and full-length human RET isoform c (amino acids M1-F1073 of Genbank accession number NP_065681.1 with two amino acid substitutions at G691S and R982C). The optimal cell clone was isolated and the resulting cell line was named HEK293 / SRELuc / hRET / hGFRa3 cl.A3. The artemin proteins hArtemin-MMH, MfArtemin-MMH, or mArtemin-MMH are disclosed in Example 2 above.

[0170] For the bioassay, cells were cultured at 2.5 × 10 using assay buffer (0.1% FBS in Opti-MEM medium). 4Cells / well were seeded into 96-well plates and incubated overnight (37° C., 5% CO2). The next day, antibodies of the invention or isotype control antibodies were serially diluted (1:3) in assay medium to final concentrations ranging from 100 nM to 1.7 pM (with additional wells for assay medium alone without test molecule) and added to cells containing a fixed concentration of artemin (500 pM h-artemin, 3 nM m-artemin, or 1 nM m-artemin) at 37° C. in 5% CO2. To assess the degree of signaling activation, artemin (h, mf, or m) was serially diluted (1:3) to final concentrations ranging from 100 nM to 1.7 pM (with additional wells for assay medium alone) and added to cells. After 5 hours of incubation, luciferase activity was assessed by addition of OneGlo™ Luciferase Assay System Reagent (Promega E6130) and relative light units (RLU) were measured using an Envision multilabel plate reader (Perkin Elmer). Results were analyzed using nonlinear regression (4-parameter logistic) in Prism® 8 to obtain EC50 and IC50 values. Percentage of inhibition was calculated using the following equation: % Inhibition = 100 × [(RLU アルテミン -RLU 阻害 ) / (RLU アルテミン -RLU ベースライン )]

[0171] In this equation, RLU アルテミン "RLU" refers to the RLU value from cells treated with a constant Artemin without antibody. 阻害 " refers to the RLU value measured at the highest concentration of antibody with a given Artemin. ベースライン " refers to the RLU value of the cells measured in the absence of ligand or antibody.

[0172] Anti-Artemin antibodies H4H33331P, H4H33335P, H4H33336P, and H4H33349P were tested in HEK293 / SRELuc / hRET / hGFRa3 cl.A3 cells containing 500 pM hArtemin, 3 nM mfArtemin, or 1 nM mArtemin, as shown in Table 8. Human, cynomolgus, and mouse artemin activated signaling through the human GFRα3 and Ret receptors with EC50 values ​​of 813 pM, 2.26 nM, and 620 pM, respectively.

[0173] Table 8. Inhibition of human, cynomolgus, and mouse artemin by anti-artemin antibodies in HEK293 / SRELuc / hRET / hGFRa3 cI.A3 cells TIFF0007579462000009.tif46148

[0174] Example 5: Inhibition of intraplantar artemin-induced thermal hyperalgesia by artemin monoclonal antibodies Animal subjects Adult C57BL / 6 male mice (Jackson Laboratories), aged 10-16 weeks, were used for the experiments. Animals were housed in groups of up to five in a temperature-controlled environment with a 12-h light / dark cycle with water and standard laboratory chow available ad libitum. All experimental procedures were approved by Regeneron's Animal Care and Use Committee and were performed by experimenters blinded to the animals' group assignment.

[0175] Acclimatization and Baselining During the week prior to intraplantar injection, mice were handled and placed in the Hargreaves behavioral testing apparatus for at least 2 hours per day to allow them to acclimate to the room and equipment. Additionally, animals were allowed to acclimate for at least 1 hour prior to all testing sessions. Baseline nociceptive responses were obtained at the end of the week.

[0176] Induction of growth factor-induced plantar thermal hyperalgesia Baseline thermal hyperalgesia was assessed using the Hargreaves test (described below) prior to subcutaneous (sc) injection of artemin antibody at 10 mg / kg. PBS (one group) or recombinant mouse artemin from R&D Systems (five groups) in 20 μl saline was injected into the hind paw three days later by placing the mice in a clear plastic restrainer with the hind paw exposed. The left hind paw was extended and 0.5 μg of artemin was injected into the plantar surface of the paw. Thermal hyperalgesia was reassessed four days later. Using pilot results from artemin injections at a power level of 0.80 and an alpha of 0.05, it was calculated that n out of 7-8 animals were required to detect return to baseline latency to withdrawal with antibody treatment. A sample size of seven animals was chosen because complete blockade of growth factor responses was expected, thus minimizing animal use by choosing the minimum recommended sample size from the power analysis.

[0177] Thermal hyperalgesia: Animals were tested for thermal sensitivity using the Hargreaves test (Hargreaves et al, Pain, 1988, 32:77-88). Mice were placed on a heated glass (IITC model 390G with a model 400 heated base) at 30°C in individual chambers and allowed to acclimate before the reading session. The apparatus was set at 15% laser intensity and testing was performed using repeated measurements (three measurements per paw) on the plantar surface of the ipsilateral hindpaw. The mean latency to withdrawal was recorded, allowing a maximum beam exposure of 20 seconds to avoid tissue damage. Latencies to withdrawal were statistically analyzed using one-way independent groups ANOVA, and treatment groups were compared with alpha set at 0.05. Tukey post-hoc tests were used to probe for significant main effects of treatment.

[0178] result Four selected human anti-artemin antibodies (H4H33331P, H4H33335P, H4H33336P, and H4H33349P) were evaluated in the intraplantar growth factor-induced hyperalgesia model. As shown in Figure 4, all four were shown to completely block artemin-induced thermal hyperalgesia in the Hargreaves test at 10 mg / kg subcutaneously, such that the withdrawal latencies were similar to the intraplantar PBS-treated group. The withdrawal thresholds of animals receiving anti-artemin antibodies were significantly different from those of animals receiving an isotype control antibody, suggesting that all four artemin antibodies were effective in inhibiting artemin-induced hyperalgesia.

[0179] Table 9: Informal sequence listing TIFF0007579462000010.tif186162TIFF0007579462000011.tif208162TIFF000 7579462000012.tif177162TIFF0007579462000013.tif208162TIFF0007579462 000014.tif181162TIFF0007579462000015.tif212162TIFF0007579462000016. tif177162TIFF0007579462000017.tif224162TIFF0007579462000018.tif82162

[0180] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the present invention, in addition to those described herein, will become apparent to those skilled in the art from the above description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. The disclosures of all patents and non-patent literature cited herein are expressly incorporated by reference in their entirety.

Claims

1. (a) an HCDR1 comprising the amino acid sequence of SEQ ID NO:64, an HCDR2 comprising the amino acid sequence of SEQ ID NO:66, an HCDR3 comprising the amino acid sequence of SEQ ID NO:68, an LCDR1 comprising the amino acid sequence of SEQ ID NO:72, an LCDR2 comprising the amino acid sequence of SEQ ID NO:74, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:76; or (b) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 6, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 8, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16, or (c) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 24, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 26, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 28, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 32, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 34, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 36, or (d) an HCDR1 comprising the amino acid sequence of SEQ ID NO: 44, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 46, an HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, an LCDR1 comprising the amino acid sequence of SEQ ID NO: 52, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 56 1. An isolated monoclonal antibody or antigen-binding fragment thereof which specifically binds to human Artemin, comprising:

2. HCDR1 comprising the amino acid sequence of SEQ ID NO:64, HCDR2 comprising the amino acid sequence of SEQ ID NO:66, HCDR3 comprising the amino acid sequence of SEQ ID NO:68, LCDR1 comprising the amino acid sequence of SEQ ID NO:72, LCDR2 comprising the amino acid sequence of SEQ ID NO:74, and LCDR3 comprising the amino acid sequence of SEQ ID NO:

76. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

3. HCDR1 comprising the amino acid sequence of SEQ ID NO:4, HCDR2 comprising the amino acid sequence of SEQ ID NO:6, HCDR3 comprising the amino acid sequence of SEQ ID NO:8, LCDR1 comprising the amino acid sequence of SEQ ID NO:12, LCDR2 comprising the amino acid sequence of SEQ ID NO:14, and LCDR3 comprising the amino acid sequence of SEQ ID NO:

16. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

4. HCDR1 comprising the amino acid sequence of SEQ ID NO:24, HCDR2 comprising the amino acid sequence of SEQ ID NO:26, HCDR3 comprising the amino acid sequence of SEQ ID NO:28, LCDR1 comprising the amino acid sequence of SEQ ID NO:32, LCDR2 comprising the amino acid sequence of SEQ ID NO:34, and LCDR3 comprising the amino acid sequence of SEQ ID NO:

36. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

5. HCDR1 comprising the amino acid sequence of SEQ ID NO:44, HCDR2 comprising the amino acid sequence of SEQ ID NO:46, HCDR3 comprising the amino acid sequence of SEQ ID NO:48, LCDR1 comprising the amino acid sequence of SEQ ID NO:52, LCDR2 comprising the amino acid sequence of SEQ ID NO:54, and LCDR3 comprising the amino acid sequence of SEQ ID NO:

56. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , comprising:

6. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising an HCVR comprising the amino acid sequence of SEQ ID NO:62, and an LCVR comprising the amino acid sequence of SEQ ID NO:

70.

7. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising an HCVR comprising the amino acid sequence of SEQ ID NO:2, and an LCVR comprising the amino acid sequence of SEQ ID NO:

10.

8. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising an HCVR comprising the amino acid sequence of SEQ ID NO:22, and an LCVR comprising the amino acid sequence of SEQ ID NO:

30.

9. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising an HCVR comprising the amino acid sequence of SEQ ID NO:42, and an LCVR comprising the amino acid sequence of SEQ ID NO:

50.

10. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:78 and a light chain comprising the amino acid sequence of SEQ ID NO:

80.

11. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:18 and a light chain comprising the amino acid sequence of SEQ ID NO:

20.

12. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:38 and a light chain comprising the amino acid sequence of SEQ ID NO:

40.

13. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, comprising a heavy chain comprising the amino acid sequence of SEQ ID NO:58 and a light chain comprising the amino acid sequence of SEQ ID NO:

60.

14. 2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, which is fully human.

15. A pharmaceutical composition comprising the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 and a pharma- ceutically acceptable carrier.

16. A nucleic acid molecule comprising a nucleotide sequence encoding the isolated monoclonal antibody or antigen-binding fragment thereof of claim 1.

17. An expression vector comprising the nucleic acid molecule of claim 16.

18. A host cell comprising the expression vector of claim 17.

19. 20. A method for producing an anti-human Artemin antibody or antigen-binding fragment thereof, comprising introducing the expression vector described in claim 17 into a host cell, growing the host cell under conditions that allow production of the antibody or antigen-binding fragment thereof, and recovering the antibody or antigen-binding fragment produced.

20. A pharmaceutical composition comprising the isolated monoclonal antibody or its antigen-binding fragment described in claim 1 for use in a method for inhibiting artemin-activated signaling in a cell, the method comprising contacting the cell with the pharmaceutical composition, thereby inhibiting artemin-activated signaling in the cell.

21. The pharmaceutical composition of claim 20 , wherein the cell is in a subject.

22. A pharmaceutical composition for treating a pain-related disease, disorder, or condition associated with increased artemin expression or activity, comprising the isolated monoclonal antibody or antigen-binding fragment thereof described in claim 1.

23. 23. The pharmaceutical composition of claim 22, wherein the pain-related disease, disorder, or condition is acute pain, chronic pain, neuropathic pain, inflammatory pain, trigeminal neuralgia, postherpetic neuralgia, generalized neuralgia, visceral pain, osteoarthritic pain, gout, radicular pain, sciatica, back pain, head and neck pain, breakthrough pain, post-operative pain, chemotherapy-induced neuropathic pain, radiotherapy-induced neuropathic pain, radiation-related pain, or cancer pain.

24. 23. The pharmaceutical composition of claim 22, wherein the pain-related disease, disorder, or condition is migraine, cluster headache, chronic headache, or tension headache.

Citation Information

Patent Citations

  • Anti-neublastin antibodies and uses thereof

    US20150344550A1

  • Compositions and methods to selectively block pain induced by cold

    US20170281756A1